Pain News and Research

Latest Pain News and Research

Takeda, Seattle Genetics announce preliminary data from brentuximab vedotin phase I study on sALCL

Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, and Seattle Genetics, Inc., today announced preliminary data from one arm of a three arm phase I, open-label, multicenter study designed to determine the safety and activity of sequential and combination treatment approaches of brentuximab vedotin with CHOP or CH-P chemotherapy in newly diagnosed patients with CD30-positive mature T- and NK- cell lymphomas.

1 Oct 2012

New evidence-based guidelines for management of acute low back pain

According to an article in the October issue of the Journal of the American College of Radiology, radiologists at Emory University Hospital, in Atlanta, and Georgia Health Sciences University, in Augusta, Ga., have developed evidence-based guidelines to assist physicians with the process of managing patients with acute low back pain.

1 Oct 2012

Exelixis announces interim data from cabozantinib phase 2 trial on metastatic CRPC

Exelixis, Inc. today announced interim data from 51 patients with metastatic castration-resistant prostate cancer (CRPC) and bone metastases receiving a 40 mg daily dose of cabozantinib in an ongoing non-randomized expansion (NRE) cohort of a phase 2 randomized discontinuation trial.

1 Oct 2012

People with SIRT1 genetic variation more likely to develop vibration-induced white finger disease

Vibration-induced white finger disease (VWF) is caused by continued use of vibrating hand held machinery (high frequency vibration >50 Hz), and affects tens of thousands of people. New research published in BioMed Central's open access journal Clinical Epigenetics finds that people with a genetic polymorphism (A2191G) in sirtuin1 (SIRT1), a protein involved in the regulation of endothelial NOS (eNOS), are more likely to suffer from vibration-induced white finger disease.

1 Oct 2012

Lilly announces new data from two Phase II ramucirumab trials on NSCLC

Eli Lilly and Company today announced new data from two Phase II ramucirumab (IMC-1121B) trials in patients with non-small cell lung cancer (NSCLC).

1 Oct 2012

Nearly 20% of people develop PTSD symptoms after low back fusion surgery

Nearly 20 percent of people who underwent low back fusion surgery developed post-traumatic stress disorder symptoms associated with that surgery, according to a recent Oregon Health & Science University study published in the journal Spine.

29 Sep 2012

New studies reveal real economic and human costs of caring for cancer patients in Europe

New studies that reveal for the first time the real economic and human costs of caring for cancer patients in Europe will be presented during the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.

29 Sep 2012

FDA approves Stiefel’s Sorilux Foam sNDA to treat for scalp psoriasis

Stiefel, a GSK company, today announced that the US Food and Drug Administration has approved a supplemental New Drug Application (sNDA) for Sorilux (calcipotriene) Foam, 0.005%. The sNDA expands the indication for Sorilux Foam to include the topical treatment of plaque psoriasis of the scalp in patients aged 18 years and older.

29 Sep 2012

GCE group, Dehaier partner to distribute EASE II products in China

Dehaier Medical Systems Ltd., an emerging leader in the development, assembly, marketing and sale of medical devices and homecare medical products in China, today announced that it has signed a two-year distribution agreement with GCE group, a leading global compressed gas-equipment company, to become the exclusive distributor for GCE's EASE II products in Mainland China.

29 Sep 2012

FDA approves Globus Medical’s SECURE-C Cervical Artificial Disc

Globus Medical, Inc., today announced that the Food and Drug Administration (FDA) has granted Premarket Approval (PMA) for the SECURE-C Cervical Artificial Disc. Clinical data from a 380 patient investigational device exemption (IDE) study demonstrate that SECURE-C is statistically superior to anterior cervical discectomy and fusion (ACDF) in terms of overall success, subsequent surgery at the index level, device-related adverse events, and patient satisfaction at 24 months.

29 Sep 2012

Research roundup: Saving money with hospital observation units, total knee replacement rates skyrocketing, Medicare patients and antibiotic overuse

The authors write: Using observation units in hospitals to provide care to certain patients can be more efficient than admitting them to the hospital and can result in shorter lengths-of-stay and lower costs. However, such units are present in only about one-third of US hospitals.

29 Sep 2012

Hip arthroscopy system launched by DePuy Mitek

DePuy Mitek, Inc., a leading developer and manufacturer of orthopaedic sports medicine products and soft tissue repair devices, announced the launch of ENDURANCE Hip Solutions, a new system of instruments and devices that marks the company’s entry into the rapidly growing field of hip arthroscopy.

28 Sep 2012

Shingles becoming more common in Australia

The herpes zoster virus, which causes shingles, is becoming more common as the population ages. In Australia the number of cases has doubled between 2000 and 2010. Hospital emergency departments report a 2–6% increase in cases per year.

28 Sep 2012

EC approves Janssen’s DACOGEN for treatment of de novo acute myeloid leukaemia

Janssen-Cilag International NV announced today that the European Commission has approved the marketing authorisation for DACOGEN(decitabine) for the treatment of adult patients (age 65 years and above) with newly diagnosed de novo or secondary acute myeloid leukaemia (AML), according to the World Health Organisation (WHO) classification, who are not candidates for standard induction chemotherapy.

28 Sep 2012

Link between work-family conflict and musculoskeletal pain among nurses

Nurses and other hospital workers, especially those who work long hours or the night shift, often report trying to juggle the demands of the job and family obligations. A study out today by The George Washington University School of Public Health and Health Services (SPHHS) suggests that the higher the work-family conflict the greater the risk that health care workers will suffer from neck and other types of musculoskeletal pain.

28 Sep 2012

ACS, AGS issue new guidelines for pre-operative care of elderly patients

New comprehensive guidelines for the pre-operative care of the nation's elderly patients have been issued by the American College of Surgeons (ACS) and the American Geriatrics Society (AGS).

28 Sep 2012

UNMCC to investigate R-ketorolac use against ovarian cancer cells

Most drugs take ten years-and frequently, more-to go from concept to FDA approval. One way to reduce this time investment is to look for already-approved drugs that could be put to new uses. And that's just what Angela Wandinger-Ness, PhD, UNM Professor of Pathology, and Laurie Hudson, PhD, UNM Professor of Pharmaceutical Sciences, have done.

28 Sep 2012

Boston Scientific receives CE MARK approval for Vercise DBS to treat Parkinson's

Boston Scientific Corporation received CE Mark approval for use of its Vercise Deep Brain Stimulation (DBS) System for the treatment of Parkinson's disease.

28 Sep 2012

RTI Biologics donates BioSet RT Allograft Paste implants to CURE International

RTI Biologics Inc. (RTI), a leading provider of orthopedic and other biologic implants, recently donated several BioSet RT Allograft Paste implants to Lemoyne, Pa.-based CURE International.

28 Sep 2012

BioLineRx’s BL-1020 safe and effective in treating schizophrenia

BioLineRx, a biopharmaceutical development company, announced today the publication of results from the Phase II EAGLE clinical trial for BL-1020, a first in class, orally available, GABA-enhanced antipsychotic for the treatment of schizophrenia, showing that BL-1020 is safe and effective in improving schizophrenia, in addition to improving cognitive impairment associated with this condition.

28 Sep 2012